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The p53 tumor-suppressor protein prevents
cancer development through various mecha-
nisms, including the induction of cell-cycle
arrest, apoptosis, and the maintenance of ge-
nome stability. We have identified a p53-induc-
ible gene named TIGAR (TP53-induced glycoly-
sis and apoptosis regulator). TIGAR expression
lowered fructose-2,6-bisphosphate levels in
cells, resulting in an inhibition of glycolysis
and an overall decrease in intracellular reactive
oxygen species (ROS) levels. These functions of
TIGAR correlated with an ability to protect cells
from ROS-associated apoptosis, and conse-
quently, knockdown of endogenous TIGAR ex-
pression sensitized cells to p53-induced death.
Expression of TIGAR may therefore modulate
the apoptotic response to p53, allowing survival
in the face ofmild or transient stress signals that
may be reversed or repaired. The decrease of
intracellular ROS levels in response to TIGAR
may also play a role in the ability of p53 to pro-
tect from the accumulation of genomic damage.
INTRODUCTION
The p53 tumor-suppressor protein plays a critical role in
responding to cellular stress and inhibiting malignant de-
velopment (Vousden and Lu, 2002). Loss of p53 function
contributes to the development of most cancers (Hollstein
et al., 1999), making the potential reactivation of p53 an at-
tractive therapeutic goal (Lain and Lane, 2003). However,
success in these endeavors depends largely on a clear un-
derstanding of the consequences of p53 activation. p53
has been shown to be involved in the induction of apopto-
sis, cell-cycle arrest, senescence, and differentiation—re-
sponses that prevent further proliferation of stressed or
damaged cells and so protect from the outgrowth of cellsharboring malignant alterations (Vogelstein et al., 2000). A
role for p53 in the repair of DNA damage has also been de-
scribed (Sengupta and Harris, 2005), and the ability of p53
to induce reversible cell-cycle arrest may contribute to the
ability of cells to repair and recover from damage before
reentering a normal proliferative state.
One of the key functions of p53 is as a transcription fac-
tor. Stress-induced activation of p53 leads to the induc-
tion of expression of a large number of p53 target genes,
several of which have been shown to play an important
role in mediating the various responses to p53 (Vogelstein
et al., 2000). For example, activation of expression of the
cyclin-dependent kinase inhibitor p21WAF1/CIP1 by p53
plays an important role in the induction of G1 cell-cycle ar-
rest (Polyak et al., 1996; Waldman et al., 1995), and the ex-
pression of the BH3-domain protein PUMA is an essential
component of p53-activated apoptotic pathways in sev-
eral cell types (Jeffers et al., 2003; Villunger et al., 2003).
Several lines of evidence suggest that one mechanism
by which the response to p53 can be regulated is through
differential activation of different groups of p53 target
genes. In particular, the ability to induce expression of
cell-cycle arrest targets without induction of the apoptotic
target genes may allow for the resolution of damage in
a stressed cell without recourse to permanent cell-cycle
arrest or cell death (Vousden, 2000).
Recent studies have suggested that another important
role for p53 in determining the death or survival of cells
is the regulation of intracellular reactive oxygen species
(ROS) levels. Organisms living in aerobic conditions are
continuously subjected to ROS, and the cellular response
to different ROS levels ranges from proliferation to growth
arrest or senescence and cell death (Martindale and Hol-
brook, 2002). A number of studies have suggested a role
for p53 in the regulation of ROS levels and therefore in
the determination of the response to stress (Macip et al.,
2003). p53 can activate numerous genes that result in in-
creased generation of ROS, which contributes to apopto-
sis (Johnson et al., 1996; Li et al., 1999; Polyak et al., 1997)
and also functions in a feedback loop in which ROS can
signal to the further activation of p53 (Chen et al., 2003;Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc. 107
Martindale and Holbrook, 2002). However, more recent
evidence suggests that p53 can also induce the expres-
sion of proteins that function to lower ROS levels and
that this antioxidant function of p53 is important in pre-
venting DNA damage and tumor development under
low-stress conditions (Sablina et al., 2005). The sestrins
have been identified as a family of p53-inducible proteins
that provide an antioxidant defense to protect cells from
hydrogen peroxide (H2O2) induced damage (Budanov
et al., 2004). p53-dependent activation of ALHD4 has
also been shown to decrease intracellular ROS (Yoon
et al., 2004). It seems likely, therefore, that the regulation
of ROS levels by different targets of p53 may play a key
role in determining the choice of response to p53.
In this study we describe TIGAR (TP53-induced glycol-
ysis and apoptosis regulator), a novel p53-inducible pro-
tein that functions to regulate glycolysis and protect
against oxidative stress. TIGAR can lower ROS levels
and decrease sensitivity to p53 and other ROS-associated
apoptotic signals and is likely to be an important compo-
nent in mediating the tumor-suppressive effects of p53.
RESULTS
Identification of TIGAR as a
p53-Inducible Gene
Microarray analysis of gene expression following p53 in-
duction that previously identified p53R2 and PUMA (Na-
kano et al., 2000) yielded one further p53-responsive
gene (accession number NM_020375; Jen and Cheung,
2005), which was named TIGAR. A time course following
p53 induction indicated that TIGAR mRNA expression
was elevated after 6 hr, with kinetics similar to those
seen for established direct targets of p53 such as
p21WAF1/CIP1 and somewhat faster than the induction of
the apoptotic target gene BAX (Figure 1A). Induction of
TIGAR mRNA by endogenous p53 was assessed by treat-
ment of wild-type p53-expressing U2OS or RKO cells
with actinomycin D (Figure 1B). A robust activation of
TIGAR mRNA expression was detected, although this
was not seen in RKO cells in which p53 was inactivated
by expression of HPV16 E6 (Figure 1B).
The TIGAR gene is located on chromosome 12p13-3
and contains six potential coding exons and two possible
p53 binding sites, one upstream of the first exon (BS1) and
one within the first intron (BS2) (Figure 1C). Binding of ei-
ther inducible p53 in SAOS-2 cells or endogenous p53 in
adriamycin-treated U2OS cells could be detected to
BS1 and BS2 (Figure 1D). While the binding of p53 to
BS2 appeared to be similar in efficiency to that seen for
the p53 binding site in the p21WAF1/CIP1 promoter, the
binding to BS1 was less efficient. This lower binding effi-
ciency was also seen in vitro, where only BS2 oligonucle-
otides could compete for binding of p53 to the high-affinity
consensus binding sequence (Figure 1E). Binding of p53
to BS2 has also recently been detected using ChIP-on-
chip analysis for novel p53 target genes (Jen and Cheung,
2005). Examination of the mouse genome revealed a sim-108 Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc.ilar organization of the mouse and human TIGAR genes,
although only one potential p53 binding site was found up-
stream of the first exon of mouse Tigar. Preliminary analy-
sis indicated that mouse cells show a weaker p53-depen-
dent induction of Tigar expression than human cells (data
not shown).
Comparison of the predicted amino acid sequence of
the TIGAR protein revealed a high degree of conservation
through vertebrate species from human to fish (Figure 2A).
We raised mouse monoclonal and rabbit polyclonal anti-
bodies against two peptides derived from sequences
within the central and the COOH-terminal parts of the pu-
tative TIGAR protein (Figure 2A). Both antibodies immuno-
precipitated Flag-tagged TIGAR (see Figure S1 in the Sup-
plemental Data available with this article online), and
Western blotting of cell lysates using these antibodies de-
tected a single endogenous protein band of 30 kDa, con-
sistent with the predicted size of TIGAR. Expression of
this protein decreased following knockdown of TIGAR ex-
pression using two independent small interfering RNAs
(siRNAs) (Figure 2B), which paralleled a reduction in
mRNA levels (data not shown). Treatment of a variety of
human cell lines expressing endogenous wild-type p53,
including tumor cell lines (U2OS, RKO, and MCF-7) and
untransformed epithelial (RPE) and fibroblast (MRC5)
cells, with adriamycin resulted in the expected stabiliza-
tion of p53 and elevation of p21WAF1/CIP1 expression
(Figure 2C). As expected from the mRNA expression anal-
ysis, induction of p53 also led to an increased expression
of TIGAR protein. The p53 dependence of this induction
was illustrated by the lack of TIGAR induction following
adriamycin treatment of the p53 null human cancer cell
line H1299 (Figure 2C). Interestingly, the tumor cell lines
H1299, U2OS, and RKO each showed a significant basal
level of TIGAR protein expression, demonstrating the
existence of p53-independent mechanisms to regulate
TIGAR expression.
p53-inducible genes can be broadly placed into two
groups: those induced rapidly by low levels of stress (gen-
erally cell-cycle arrest or antioxidant targets) and those
that are induced by higher levels of p53/stress (generally
apoptotic targets) (Sablina et al., 2005). The results shown
in Figure 1A suggested that TIGAR expression is rapidly
induced in response to p53, like p21WAF1/CIP1. Consistent
with this observation, activation of endogenous p53 by
low levels of adriamycin treatment in RKO cells resulted
in the induction of TIGAR and p21WAF1/CIP1 protein expres-
sion, while higher levels of stress were required to elevate
expression of the apoptotic protein PIG3 (Figure 2D). In-
terestingly, extended exposure to stress and the induction
of the p53-mediated apoptotic response correlated with a
reduction in the expression of TIGAR and p21WAF1/CIP1,
suggesting that TIGAR may play a role in controlling the
switch in p53 response (Figure 2E and Figure S2A). An-
other mechanism that can distinguish classes of p53 tar-
gets is their transcriptional sensitivity to the p53R175P
mutant, which selectively fails to activate the expression
of some apoptotic target genes (Ludwig et al., 1996).
Figure 1. Identification of TIGAR as a p53-Inducible Gene
(A) Northern blot using specific probes showing expression of p53, TIGAR, p21WAF1/CIP1, and BAX in p53-inducible SAOS-2 cells without (0 hr) and
with (1.5 to 24 hr) doxycycline treatment (2 mg/ml). GAPDH expression was examined as a loading control.
(B) Northern blot using TIGAR-specific probes, showing expression of TIGAR in RKO, RKO/E6, and U2OS cells without () and with (+) actinomycin D
treatment (5 nM) for 24 hr.
(C) The genomic structure of human TIGAR, showing the exon/intron organization and the two potential p53 binding sites upstream of the first exon
(TIGAR BS1) and within the first intron (TIGAR BS2) compared to the consensus p53 binding site (p53 CBS). R, purine; Y, pyrimidine; W, adenine or
thymine. The predicted initiation codon (AUG) is also indicated.
(D) ChIP assay for TIGAR and p21WAF1/CIP1 in p53-inducible SAOS-2 cells without and with doxycycline treatment (2 mg/ml) for 24 hr and in U2OS cells
without and with adriamycin treatment (0.2 mg/ml) for 24 hr. Crosslinked p53 protein/DNA complexes were immunoprecipitated with an anti-p53 an-
tibody (DO-1). Control immunoprecipitations were carried out without antibody (Ab ()) or with normal mouse IgG (Mouse IgG).
(E) EMSA showing the DNA binding activity of p53 to oligonucleotides containing a consensus p53 binding site (BB9), TIGAR BS1, and TIGAR BS2.
The DNA binding activity of in vitro-translated p53 protein was activated using the COOH-terminal anti-p53 antibody pAb421 as indicated. Specificity
of the binding was checked using an excess (503) of nonradiolabeled competitive TIGAR BS1, TIGAR BS2, and BB9 oligonucleotides.Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc. 109
Figure 2. TIGAR Protein Is Induced by p53
(A) Multiple alignment of human TIGAR protein with homologous proteins from different species. The alignment was generated using the ClustalW
program. Black shading shows amino acid residues conserved in aligned sequences. The positions of the aligned regions in the respective protein
sequences are indicated, as are the peptides used to raise antibodies.
(B) Expression of endogenous TIGAR in U2OS cells transfected with scrambled siRNA (1), TIGAR siRNA1 (2), or TIGAR siRNA2 (3). TIGAR was de-
tected by Western blotting using the anti-TIGAR monoclonal antibody. Cdk4 expression was examined as a loading control.
(C) Expression of endogenous p53, TIGAR, and p21WAF1/CIP1 in various cells without () and with (+) adriamycin treatment (0.2 mg/ml) for 24 hr. p53,
TIGAR, and p21WAF1/CIP1 were detected by Western blotting. b-actin expression was examined as a loading control.
(D) Western blot showing expression of endogenous p53, PIG3, TIGAR, and p21WAF1/CIP1 in RKO cells without (0) and with treatment with an increas-
ing amount (2.5–200 ng/ml) of adriamycin for 24 hr.
(E) Western blot showing expression of endogenous p53, PIG3, TIGAR and p21WAF1/CIP1 in RKO cells without (0) and with treatment with 200 ng/ml
adriamycin for the indicated times. b-actin expression was examined as a loading control.110 Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc.
Like p21WAF1/CIP1, TIGAR was activated by p53R175P,
but not the transcriptionally inactive p53R175H mutant
(Figure S2B).
TIGAR Shows Similarities to the Bisphosphatase
Domain of PFK-2/FBPase-2
Having established TIGAR as a bone fide p53 target, we
examined the TIGAR protein sequence for any information
about possible function. Using predicted amino acid se-
quence on the entire genomic database, TIGAR was found
to share similarity with proteins in the phosphoglycerate
mutase (PGM) family. This similarity was mainly limited
to the catalytic regions, and within these, the highest de-
gree of similarity was observed with the bisphosphatase
domain of the different isoform products of the four genes
(pfkfb1–4) encoding the enzyme 6-phosphofructo-2-ki-
nase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2)
(Figure 3A) (Okar et al., 2001). PFK-2/FBPase-2 is a bifunc-
tional enzyme with both kinase and bisphosphatase activ-
ities that are catalyzed at different sites on each subunit of
this protein. The kinase domain, PFK-2, is localized within
the NH2-terminal part of the enzyme, and the bisphospha-
tase domain, FBPase-2, is in the COOH-terminal region.
Interestingly, the similarity between TIGAR and PFK-2/
FBPase-2 is limited to the bisphosphatase domain. Al-
though overall the sequence similarity between TIGAR
and FBPase-2 was relatively weak, the regions in the
FBPase-2 domain that have previously been identified
as essential for catalytic activity are well conserved in
TIGAR (Figure 3A). These include the three amino acids
(H, E, and H; Figure 3A) that constitute the catalytic triad
of the active site (Lin et al., 1992) and the RHG signature
(Figure 3A, region 1) that is characteristic of the PGM fam-
ily (Bazan et al., 1989). While TIGAR shows similarity with
these regions of all members of the PGM family, se-
quences surrounding the third residue (H) of the catalytic
triad are more similar between TIGAR and the corre-
sponding region in the bisphosphatase domain of PFK-
2/FBPase-2 than the other PGM family members
(Figure 3A, region 2). These regions are also conserved
in TIGAR of different species (Figure 2A). Taken together,
these observations suggest that TIGAR may function as
a fructose bisphosphatase but would not be predicted
to show any kinase activity associated with the full-length
PFK-2/FBPase.
PFK-2/FBPase-2 regulates both the synthesis (through
PFK-2) and the degradation (through FBPase-2) of intra-
cellular fructose-2,6-bisphosphate (Fru-2,6-P2), a potent
positive allosteric effector of 6-phosphofructo-1-kinase
(PFK-1), which stimulates glycolysis. Fru-2,6-P2 is also
an inhibitor of fructose-1,6-bisphosphatase (FBPase-1),
a regulatory enzyme of gluconeogenesis (Okar et al.,
2001). The function of FBPase-2 is therefore to lower
Fru-2,6-P2 levels, thereby decreasing the activity of
PFK-1 and enhancing the activity of FBPase-1, and so in-
hibiting glycolysis.
In order to determine whether TIGAR can function in
a manner similar to FBPase-2, we examined the levels ofFru-2,6-P2 in cells either transiently or constitutively over-
expressing TIGAR following transfection (Figure 3B).
These experiments showed a reproducible decrease in
Fru-2,6-P2 levels following TIGAR expression. The extent
of this decrease was comparable to that seen following
expression of a truncated form of PFK-2/FBPase-2 ex-
pressing only the bisphosphatase domain (FBPase-2)
(Figure 3B). In order to assess whether the three amino
acids in TIGAR that are analogous to the key residues of
the catalytic triad in the FBPase-2 domain (H, E, and H;
Figure 3A) are active sites for a putative bisphosphatase
activity, we generated the TIGAR-TM mutant (triple mu-
tant H11A/E102A/H198A). Interestingly, mutation in these
amino acids, shown to be necessary for enzyme activity in
FBPase-2, abrogated the ability of TIGAR expression to
lower Fru-2,6-P2 levels (Figure 3B). To establish an activity
for endogenous TIGAR, we examined the effect of siRNA
knockdown (Figure 3C). As predicted, lowering TIGAR ex-
pression resulted in an increase in Fru-2,6-P2 levels. Fur-
ther analysis showed that the decrease of Fru-2,6-P2
levels in cells overexpressing TIGAR correlated with a de-
crease in glycolytic rates in the murine IL-3-dependent
pro-B FL5.12 cell line (Figure 3D) and human U2OS cells
(Figure 3E). Although this effect was modest, it was similar
to the extent of reduction in glycolysis seen following ex-
pression of the FBPase-2 domain (Figure 3E). Further-
more, knockdown of endogenous TIGAR expression us-
ing siRNAs resulted in an increase in glycolytic rates
(Figure S3).
TIGAR Expression Can Modulate Apoptosis
in a Cell-Type-Dependent Manner
Several recent studies have shown that modulation of gly-
colytic rates can have a profound effect on the apoptotic
sensitivity of cells (Vander Heiden et al., 2001). After
growth-factor withdrawal, the FL5.12 cell line has been
shown to be extremely sensitive to changes in glycolysis,
with lower glycolytic rates leading to enhanced cell death
by apoptosis (Vander Heiden et al., 2001). IL-3-deprived
cells overexpressing TIGAR showed enhanced apoptosis
(Figure 4A), which correlated with the level of TIGAR ex-
pression and the decrease in glycolytic rate (Figure 3D).
While these results are consistent with previous published
observations linking inhibition of glycolysis with enhanced
death in this cell system, we were also interested in a se-
ries of studies showing that decrease in flux through the
major glycolytic pathway by inhibition of PFK-1 activity
might be linked to increased resistance to cell death
(Boada et al., 2000; Perez et al., 2000). More specifically,
overexpression of the FBPase-2 domain showed that
the inhibition of PFK-1 resulted in the accumulation of
fructose-6-phosphate (F6P). F6P is then isomerized to
glucose-6-phosphate (G6P) in cells, and this accumulated
G6P is diverted into the pentose phosphate pathway
(PPP), an alternative metabolic pathway that can provide
substrates for the later steps in glycolysis. The increased
flow through the PPP lowered apoptosis due to an in-
creased generation of reduced glutathione and removalCell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc. 111
Figure 3. TIGAR Is a Protein with Similarities to PFK-2/FBPase-2 that Can Inhibit Glycolysis
(A) Multiple alignment of human TIGAR protein with the sequences of the products of the four PFK-2/FBPase-2 genes, pfkfb1, pfkfb2, pfkfb3, and
pfkfb4. The alignment was generated using the MACAW program. Black shading shows amino acid residues conserved in aligned sequences.
The two essential domains for activity are indicated (1 and 2), and the three amino acids that are part of the catalytic triad of the bisphosphatase
are denoted by asterisks. The positions of the aligned regions in the respective protein sequences are indicated.
(B) Intracellular Fru-2,6-P2 concentration determination in U2OS control cells (clone Cont#3) and cells stably overexpressing Flag-tagged TIGAR
(clones TIGAR#5 and TIGAR#10) (left panel) and U2OS cells transiently transfected with empty vector pcDNA3.1 or expression plasmids for Flag-
tagged TIGAR, HA-tagged FBPase-2, or Flag-tagged TIGAR-TM (right panel). In this and all other figures, unless stated otherwise, the mean and stan-
dard deviation of the mean for at least three independent experiments are shown.112 Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc.
of ROS in cells. The similarity in function between TIGAR
and the FPBase-2 domain prompted us to examine the ef-
fect of TIGAR overexpression on p53-induced apoptosis,
which has been associated with increased ROS (Polyak
et al., 1997). This system is different from the IL-3-with-
drawal-induced death seen in the FL5.12 cells, which is
neither clearly p53 dependent nor ROS generating. In
U2OS cells, the apoptosis induced by p53 expression
was lowered by coexpression of either TIGAR or the iso-
lated FBPase-2 domain (Figure 4B). TIGAR overexpres-
sion lowered even background levels of apoptosis, and,
when coexpressed with p53, TIGAR decreased apoptotic
rates slightly more efficiently than expression of FBPase-2
(Figure 4C). To determine whether this survival effect re-
flects levels of TIGAR expression, we analyzed different
populations of transfected cells with no, low, or high
TIGAR levels and showed that increased levels of TIGAR
correlated with decreased apoptosis (Figure 4D). Al-
though TIGAR clearly modulated the apoptotic response
seen after extended stress, the cell-cycle arrest induced
by p53 following a shorter exposure to stress was unaf-
fected by TIGAR (Figure S4). This is consistent with reten-
tion of the ability to induce p21WAF1/CIP1 (Figure 2E). Inter-
estingly, coexpression of full-length PFKFB1, which, like
other PFK-2/FBPase-2 isoforms, has a kinase/bisphos-
phatase ratio that results in a net increase of phosphofruc-
tokinase activity and an accumulation of Fru-2,6-P2 in the
cells (Perez et al., 2000), can overcome the effect of TIGAR
on apoptosis (Figure 4E). These results indicated that an
FBPase-2 activity of TIGAR may be responsible for its abil-
ity to reduce apoptosis, a suggestion that was further sup-
ported by the analysis of TIGAR mutants that were altered
in the key residues essential for bisphosphatase activity
(Figure 5A). While each of these mutants was efficiently
expressed (Figure 5B), only wild-type TIGAR efficiently
inhibited p53-induced apoptosis (Figure 5C). The loss of
activity of the TIGAR-TM mutant correlated with the failure
of this mutant to lower intracellular Fru-2,6-P2 levels
(Figure 3B) and decrease the glycolytic rate (Figure 3E).
To determine the role of endogenous TIGAR in modulat-
ing p53-dependent apoptosis, we used siRNAs to knock
down TIGAR expression in a number of cell lines. In
U2OS cells, siRNAs that reduced TIGAR expression
(Figure 2B) led to an enhanced sensitivity of cells to apo-
ptosis following activation of endogenous p53 by adria-
mycin (Figure 6A) or overexpression of ectopic p53 by
transfection (Figure 6B). To confirm that the enhanced ap-
optosis is a specific result of a decrease in TIGAR levels
rather than an off-target effect of the siRNAs, we con-
structed a siRNA-resistant TIGAR mutant that expressed
wild-type TIGAR protein. Expression of this construct re-versed the effect of the TIGAR siRNA, allowing expression
of TIGAR protein (Figure S7) and a decrease in apoptosis
(Figure 6B). Knockdown of endogenous TIGAR expres-
sion also resulted in enhanced apoptosis following p53
activation in a number of other cell lines, including MCF-
7 cells (Figure S5A), RKO cells (Figure S5B), and
HCT116 cells (Figure 6C). To further assess the ability of
TIGAR to modulate p53-induced apoptosis, we examined
the effect of treatment of the cells with Nutlin-3, a direct
and specific activator of p53 (Vassilev et al., 2004). As pre-
viously reported, treatment with Nutlin-3 enhanced death
in HCT116 cells in a manner dependent on the presence of
p53 (Figure 6C). Although inhibition of TIGAR expression
enhanced the p53-dependent death as expected, no
increase in apoptosis in p53 null cells treated with Nut-
lin-3 was observed (Figure 6C), demonstrating a direct
role of TIGAR in modulating the p53 response. Interest-
ingly, p21WAF1/CIP1 was not required for TIGAR function
(Figure S5C).
The isolated bisphosphatase domain of PFK-2/
FBPase-2 (Boada et al., 2000) functions by decreasing
ROS levels and therefore lowers apoptosis induced di-
rectly by H2O2 treatment of cells. Similarly, protection
against apoptosis induced by H2O2 was also seen follow-
ing overexpression of TIGAR in both p53-expressing cells
(U2OS) and in a p53 null background (H1299) (Figure 6D).
We also found that TIGAR lowered the sensitivity of cells
to sodium n-butyrate treatment, a p53-independent apo-
ptotic signal that can induce ROS (Hsiao et al., 2006)
(Figure 6E). Furthermore, knockdown of TIGAR enhanced
the p53-independent apoptosis induced by adriamycin
(Figure S5C), a response that reflects increased ROS
levels (Tsang et al., 2003). These results are consistent
with an antiapoptotic function of TIGAR in modulating
ROS-sensitive apoptosis rather than a direct or specific in-
hibition of p53 activation or function. Importantly, apopto-
sis induced by the anti-Fas antibody CH11, which does
not require ROS (Huang et al., 2003), was not affected
by TIGAR expression either in U2OS cells (Figure 6F) or
in HeLa cells, where the anti-Fas antibody directly induces
cell death without additional treatment with cycloheximide
(data not shown). These results, in conjunction with the ef-
fect of TIGAR in FL5.12 cells (Figure 4A), demonstrate that
TIGAR selectively inhibits ROS-sensitive apoptosis.
TIGAR Functions through the Pentose Phosphate
Pathway to Decrease Intracellular ROS Levels
The suggestion that the antiapoptotic activities of TIGAR
are a consequence of the regulation of glycolysis predicts
that TIGAR should not be able to function under circum-
stances where glycolysis has been blocked. We therefore(C) Intracellular Fru-2,6-P2 concentration determination in U2OS cells transiently transfected with scrambled siRNA or TIGAR siRNA1.
(D) Glycolytic rate in FL5.12 control cells (clone Cont#6) and cells stably overexpressing Flag-tagged TIGAR (clone TIGAR#7), determined by mea-
suring the conversion of 5-3H-glucose to 3H-H2O. FL5.12 cells were grown with (+IL-3) or without (IL-3) interleukin-3 for 4 hr.
(E) Glycolytic rates in U2OS control cells (clone Cont#3) and cells stably overexpressing Flag-tagged TIGAR (clones TIGAR#5 and TIGAR#10) (left
panel) and in U2OS cells transiently transfected with empty vector pcDNA3.1 or expression plasmids for Flag-tagged TIGAR, HA-tagged FBPase-
2, or Flag-tagged TIGAR-TM (right panel). Glycolytic rates were determined by measuring the conversion of 5-3H-glucose to 3H-H2O.Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc. 113
Figure 4. TIGAR Expression Can Modulate Apoptosis in a Cell-Type-Dependent Manner
(A) FL5.12 cells stably expressing Flag-tagged TIGAR (TIGAR#7, #12, and #13) and control cells (Cont#6) were cultured following IL-3 withdrawal for
the indicated times, and cell viability was measured using annexin V staining. The percentage of cell death following growth-factor withdrawal over
time is shown for one representative experiment. Levels of TIGAR expression in each line were determined by Western blotting with an anti-Flag an-
tibody; levels of cdk-4 expression were determined as a loading control.
(B) Apoptosis in U2OS cells, as measured by cells with a sub-G1 DNA content, 48 hr following transfection of expression plasmids for various com-
binations of wild-type p53, Flag-tagged TIGAR, and/or HA-tagged FBPase-2 or empty vector pcDNA3.1 as a control.
(C) Apoptosis in U2OS cells 48 hr after transfection of expression plasmids for various combinations of wild-type p53, Flag-tagged TIGAR, and/or HA-
tagged FBPase-2 or empty vector pcDNA3.1 as a control. Expression of exogenous HA-tagged FBPase-2 was detected by Western blotting.
(D) Apoptosis in U2OS cells. Twenty-four hours following transfection of expression plasmids for Flag-tagged TIGAR or empty vector pcDNA3.1 as
a control, cells were left untreated or treated with 0.5 or 1 mg/ml adriamycin. The apoptotic rate, as measured by cells with a sub-G1 DNA content, was114 Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc.
Figure 5. TIGAR Mutants Show an Impaired Antiapoptotic Activity
(A) Schematic representation of the predicted domain structure of the human TIGAR protein, indicating the two regions (amino acids 10–12 and 193-
210) and the three amino acids (H11, E102, and H198) essential for activity. TIGAR-DRHG, TIGAR-DPFK, and TIGAR-TM (H11A/E102A/H198A) mu-
tants are shown.
(B) Expression of Flag-tagged TIGAR, TIGAR-DPFK, TIGAR-DRHG, and TIGAR-TM following transient transfection of U2OS cells. TIGAR proteins
were detected by Western blotting using an anti-Flag antibody. b-actin expression was examined as a loading control.
(C) Apoptosis in U2OS cells, as measured by cells with a sub-G1 DNA content, 48 hr after transfection of expression plasmids for various combina-
tions of wild-type p53, Flag-tagged TIGAR, TIGAR-TM, TIGAR-DRHG, and/or TIGAR-DPFK or empty vector pcDNA3.1 as a control.examined the effects of TIGAR expression on p53-in-
duced apoptosis in U2OS cells treated with 2-deoxyglu-
cose (2-DG), a glucose analog that specifically inhibits
glycolysis. 2-DG can be phosphorylated to 2-deoxyglu-
cose-6-phosphate (2-DG6P), which cannot be metabo-
lized further through the glycolytic pathway, although it
retains some ability to be metabolized into PPP intermedi-
ates (Le Goffe et al., 2002; Ozer et al., 2001). As expected,
expression of TIGAR under these conditions was unable
to reduce p53-induced cell death (Figure 7A).
Our model for TIGAR function also predicts a require-
ment for nicotinamide adenine dinucleotide (NADPH)
produced by the PPP to generate reduced glutathione
(GSH) and thereby decrease levels of ROS. GSH, a tripep-tide with a free sulfhydryl group, is required to combat ox-
idative stress and maintain the normal reduced state in the
cell (Kletzien et al., 1994). Oxidized glutathione (GSSG) is
reduced to GSH by glutathione reductase using NADPH,
which is generated by glucose-6-phosphate-dehydroge-
nase (G6PDH), the rate-limiting enzyme of the PPP,
and 6-phosphogluconate dehydrogenase. Glutathione
peroxidase reduces H2O2 to H2O by oxidizing GSH. Con-
sequently, the PPP plays an essential role in protection
from oxidative-stress-induced apoptosis (Fico et al.,
2004; Tian et al., 1999), and an ability of TIGAR to increase
the flux through the PPP should lead to the removal of in-
tracellular ROS. To directly test the involvement of this
pathway in the function of TIGAR, we examined the effectsmeasured 48 hr later. For Western blotting, cells were sorted simultaneously into different populations (no, low, or high expression) based on Flag-
tagged TIGAR protein expression using the BD FACSVantage SE Flow Cytometer. Endogenous p53 and Flag-tagged TIGAR were detected by West-
ern blotting using an anti-p53 antibody (DO-1) and an anti-Flag monoclonal antibody. b-actin expression was examined as a loading control.
(E) Apoptosis in U2OS cells 48 hr after transfection of expression plasmids for various combinations of wild-type p53, Flag-tagged TIGAR, and/or
wild-type PFKFB1 or empty vector pcDNA3.1 as a control. Expression of exogenous PFKFB1 was detected by Western blotting.Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc. 115
Figure 6. Modulation of TIGAR Expression Influences ROS-Sensitive Apoptosis
(A) Apoptosis in U2OS cells left untreated or treated (+Adr.) with 1 mg/ml adriamycin to induce apoptosis in the presence of either scrambled or TIGAR
siRNAs as indicated. The apoptotic rate, as measured by cells with a sub-G1 DNA content, was measured 48 hr later.
(B) Flow cytometric analysis of U2OS cells transfected with scrambled siRNA or TIGAR siRNA1 and then, 24 hr later, transiently transfected with ex-
pression plasmids for wild-type p53, Flag-tagged TIGAR (siRNA1 resistant), or empty vector pcDNA3.1 as a control. The apoptotic rate, as measured
by cells with a sub-G1 DNA content, was determined after 48 hr.
(C) Apoptosis in HCT116 cells (wild-type and p53/) left untreated or treated (+Nutlin-3) with 10 mM of Nutlin-3 (Cayman Chemicals) to induce p53-
dependent apoptosis in the presence of either scrambled or TIGAR siRNAs as indicated. After 48 hr, the apoptotic rate was measured by percentage
of cells with a sub-G1 DNA content. p53 and TIGAR were detected by Western blotting. b-actin expression was examined as a loading control.
(D) Apoptosis, as measured by cells with a sub-G1 DNA content, in U2OS (top panel) and H1299 (bottom panel) cells following transient transfection of
expression plasmids for Flag-tagged TIGAR or empty vector pcDNA3.1 as a control. After 48 hr, transfected cells were incubated for 10 hr (U2OS) and
20 hr (H1299) in the presence of the indicated concentrations of H2O2.
(E) Apoptosis, as measured by cells with a sub-G1 DNA content, in U2OS cells following transfection of expression plasmids for Flag-tagged TIGAR or
empty vector pcDNA3.1 as a control. After 48 hr, transfected cells were incubated for 24 hr in the presence of 5 mM sodium n-butyrate.116 Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc.
of TIGAR expression on apoptosis in cells treated with
trans-androsterone (TA), a specific inhibitor of G6PDH.
As predicted, inhibition of the PPP prevented the antia-
poptotic activity of TIGAR (Figure 7B).
Since TIGAR inhibits ROS-associated apoptosis and re-
quires the PPP to function, we determined directly the ef-
fect of TIGAR expression on the GSH/GSSG ratio. As ex-
pected, expression of TIGAR or the isolated FBPase-2
domain increased the GSH/GSSG ratio, while decrease
of endogenous TIGAR expression lowered it (Figure 7C).
Finally, we measured intracellular ROS in cells overex-
pressing wild-type TIGAR, the TIGAR-TM mutant, and
the isolated FBPase-2 domain. Expression of TIGAR pre-
vented a p53-induced increase in ROS levels in U2OS cells
(Figure 7D). TIGAR expression also lowered the increase in
ROS levels resulting from treatment of cells with adriamy-
cin to an extent similar to that seen with the FBPase-2 do-
main (Figure 7E). The mutant TIGAR protein had no effect
on ROS levels. Knockdown of endogenous TIGAR expres-
sion using siRNA slightly enhanced intracellular ROS levels
in U2OS cells, an effect that was more evident following in-
duction of ROS by adriamycin (Figure 7F; Figure S6).
Taken together, these results suggest that TIGAR expres-
sion can modulate the levels of intracellular ROS.
Our results have demonstrated that TIGAR functions to
reduce cellular sensitivity to ROS-associated apoptosis
rather than directly affecting p53 function. However, in
light of previous studies showing that increased ROS
levels can signal to stabilize and activate p53 (Chen
et al., 2003; Martindale and Holbrook, 2002), we examined
the relationship between TIGAR and p53 more closely. In
cotransfection, modulation of TIGAR expression only
slightly affected exogenous p53 levels (Figure S7A), an ef-
fect that was not detectable when examining the levels of
endogenous p53 (Figure 4D; Figures S7A and S7B). In-
duction of p53 target genes was also only slightly affected
by TIGAR expression. These results indicate that, while
the regulation of intracellular ROS levels has the potential
to feed back to the p53 response under some conditions,
TIGAR does not directly modulate p53.
DISCUSSION
In this paper, we report the identification of a new p53-
inducible gene named TIGAR. Expression of TIGAR
reduced ROS levels and protected from ROS-sensitive
apoptotic responses, such as those induced by p53. How-
ever, ROS-insensitive apoptosis was not decreased by
TIGAR, and, as illustrated by the effects of TIGAR expres-
sion in FL5.12 cells, modulation of glycolysis can also
increase sensitivity to apoptosis under some circum-
stances. The effects of TIGAR expression on cell survival
are therefore likely to be cell and context dependent. Al-though we have not demonstrated bisphosphatase activ-
ity directly, TIGAR shows functional similarities to the bi-
sphosphatase domain of PFK-2/FBPase-2 in modulating
glycolysis, ROS levels, and apoptosis. However, the se-
quence similarity between TIGAR and the FBPase-2 do-
main is limited, and we have reproducibly noted a more ef-
ficient protection from apoptosis following overexpression
of TIGAR compared to the FBPase-2 domain. It is possible
that TIGAR also has other activities that contribute to the
protection from apoptotic stimuli.
While we found TIGAR to be conserved in vertebrates,
there is no clear homolog of TIGAR in Drosophila or Cae-
norhabditis elegans. There is also some evidence for the
expression of an alternative form of TIGAR with an altered,
truncated NH2-terminal region, although this is detected
at only very low levels by RT-PCR, with no evidence for
protein expression by Western blotting. We have therefore
not yet pursued the functional consequences of expres-
sion of this putative protein.
Our identification of TIGAR as a p53-inducible gene ex-
tends the complex balance of ROS-inducing and ROS-
decreasing signals propagated by p53. The ability of
p53 to protect the genome from oxidative damage by de-
creasing ROS levels has recently been shown to play
a critical role in tumor suppression (Sablina et al., 2005),
and it seems most likely that TIGAR will contribute to
this activity. Indeed, our data suggest that TIGAR falls
into the group of genes that are activated by low levels
of stress and may play a role in the nonrestrictive tu-
mor-suppressor function of p53. Interestingly, the switch
from p53-induced cell-cycle arrest to apoptosis following
prolonged stress is associated with a decrease in expres-
sion of both TIGAR and p21WAF1/CIP1, suggesting that the
induction of the apoptotic response may reflect the loss of
protection by these p53-inducible survival signals. p53
also plays a role in allowing DNA repair through several
mechanisms (Sengupta and Harris, 2005), and the activa-
tion of p53-dependent survival signals such as TIGAR
may be essential to allow the opportunity for such repair.
Indeed, TIGAR may contribute directly to DNA repair, in
addition to decreasing ROS levels and allowing cell sur-
vival, since the intermediate metabolites of the PPP, in-
cluding NADPH and ribose-5-phosphate, are important
precursors of DNA biosynthesis and repair (Zhang et al.,
2003). Our preliminary analysis of tumor cell lines clearly
shows that TIGAR expression is not completely p53 de-
pendent, with relatively high levels of TIGAR expressed
in some p53 null cells. It will therefore be of interest to
identify factors that influence TIGAR expression or func-
tion independently of p53. Finally, one of the hallmark of
cancer cells is an increased glycolytic rate (Warburg,
1956), which is frequently accompanied by elevated
levels of Fru-2,6-P2 (Chesney et al., 1999; Nissler et al.,(F) Flow cytometric analysis of U2OS cells transfected with expression plasmids for Flag-tagged TIGAR or empty vector pcDNA3.1 as a control and
then, 24 hr later, left untreated or treated with CH11 (anti-Fas antibody, Upstate) in the presence of cycloheximide (1 mg/ml). The apoptotic rate, as
measured by cells with a sub-G1 DNA content, was measured 24 hr later.Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc. 117
Figure 7. TIGAR Functions through the Pentose Phosphate Pathway to Decrease Intracellular ROS Levels
(A) Effect of inhibition of the glycolytic pathway by 6 mM 2-deoxyglucose (2-DG) on TIGAR antiapoptotic activity in U2OS cells. Cells were analyzed by
flow cytometry 48 hr after transfection with expression plasmids for wild-type p53 and/or Flag-tagged TIGAR or empty vector pcDNA3.1 as a control.
(B) Effect of inhibition of the pentose phosphate pathway by 50 mM trans-androsterone (TA) on TIGAR antiapoptotic activity in U2OS cells. Cells were
analyzed by flow cytometry 48 hr after transfection with expression plasmids for wild-type p53 and/or Flag-tagged TIGAR or empty vector pcDNA3.1
as a control.
(C) GSH/GSSG ratio (normalized to the controls) in U2OS cells transiently transfected with empty vector pcDNA3.1 or expression plasmids for Flag-
tagged TIGAR, HA-tagged FBPase-2, or Flag-tagged TIGAR-TM (left panel) or with scrambled or TIGAR siRNAs (right panel).
(D) ROS levels in U2OS cells transiently cotransfected for 12 hr with expression plasmids for GFP and wild-type p53 and/or Flag-tagged TIGAR or
empty vector pcDNA3.1. Cells were stained with DHE and measured by counting ROS-positive versus GFP-positive cells using a fluorescence mi-
croscope. The results are expressed as the mean and standard deviation of the mean of DHE fluorescence from three experiments.
(E) Basal (untreated) and adriamycin-induced (+Adr., 0.15 mg/ml, 10 hr) ROS levels in U2OS cells transiently cotransfected with expression plasmids118 Cell 126, 107–120, July 14, 2006 ª2006 Elsevier Inc.
1995). Whether changes in TIGAR expression can con-
tribute or respond to these cancer-specific effects also re-
mains to be determined.
EXPERIMENTAL PROCEDURES
Array Screening and Cloning of TIGAR
Total RNA from p53-inducible SAOS-2 cells with or without treatment
with doxycycline was screened by Incyte Pharmaceutical, Inc. on the
human UniGEM V microarray. One EST tag was identified and used
in 50 RACE (SMART RACE, Clontech) to obtain the TIGAR cDNAs.
RNA Analysis
Northern blot analysis was carried out as previously described (Na-
kano et al., 2000) using probes described in the Supplemental Exper-
imental Procedures.
Chromatin Immunoprecipitation Assay
U2OS cells treated for 24 hr with 0.2 mg/ml adriamycin and p53-induc-
ible SAOS-2 cells treated with 2.0 mg/ml doxycycline were subjected to
chromatin immunoprecipitation (ChIP) assay (EZ ChIP kit, Upstate Bio-
technology) as detailed in the Supplemental Experimental Procedures.
Electrophoretic Mobility Shift Assay
The binding of p53 to DNA fragments derived from regions upstream of
the start codon and in the first intron of TIGAR was analyzed by elec-
trophoretic mobility shift assay (EMSA) as described in the Supple-
mental Experimental Procedures.
Plasmids
Flag-tagged TIGAR and TIGAR mutants were generated by RT-PCR
using primers described in the Supplemental Experimental Proce-
dures. The pcDNA3-PFK-2/FBPase-2 plasmid expressing the rat liver
PFK-2/FBPase-2 enzyme and the pcDNA3-HA-tagged FBPase-2
plasmid expressing only the bisphosphatase domain have been de-
scribed previously (Perez et al., 2000).
Cell Lines, Transfections, and Inhibition of TIGAR Expression
Cell lines used in this study have been previously described and are ref-
erenced in the Supplemental Experimental Procedures. Transfections
were carried out using the Lipofectamine 2000 reagent (Invitrogen),
and cells were harvested for flow cytometry (to allow sorting for trans-
fected cells based on CD20 or Flag expression) or protein analysis at
the indicated times. The sequences of siRNAs used to knock down
TIGAR are described in the Supplemental Experimental Procedures.
Measurement of Fru-2,6-P2 Levels and Glycolysis
Fru-2,6-P2 levels were determined by activation of pyrophosphate-de-
pendent PFK-1, and glycolysis was measured by monitoring the con-
version of 5-3H-glucose to 3H2O, as described previously (Liang et al.,
1997) and detailed in the Supplemental Experimental Procedures.
Protein Analysis and Generation of Anti-TIGAR Antibodies
Rabbit polyclonal antibody to TIGAR was raised against two 15
amino acid peptides corresponding to the exon 6-encoded region
in the human TIGAR protein (ADQKEQFSQGSPSNC and
CMNLQDHLNGLTETR). The second of these peptides was also
used to generate a mouse monoclonal antibody to TIGAR. Human
p53, p21WAF1/CIP1, PIG3, cdk-4, and b-actin proteins were detected
using the antibodies DO-1, OP64 (Calbiochem), PC268 (Calbiochem),sc-260 (Santa Cruz Biotechnology), and #4967 (Cell Signaling), re-
spectively. Rat PFKFB1 was detected using E-16 (Santa Cruz). Wild-
type and mutant Flag-tagged TIGAR were detected using the anti-
Flag M2 antibody (Sigma). HA-tagged FBPase-2 was detected using
anti-HA F-7 antibody (Santa Cruz Biotechnology).
Flow Cytometry
To study the effect of overexpression of TIGAR on apoptosis, cells
were transfected with plasmids of interest and, in some cases, co-
transfected with a plasmid expressing CD20. Cells were harvested
at 24, 48, or 72 hr after transfection, stained for CD20 or Flag expres-
sion, and analyzed by flow cytometry (FACScan, Becton Dickinson) as
previously described (Rowan et al., 1996). Transfection efficiencies
were determined by the percentage of cells positive for CD20 or
Flag, and, within each cell line, minimal variation between different
transfections was observed. Apoptosis was assessed using sub-G1
DNA content, the Annexin-V-FITC Apoptosis Detection Kit (BD Phar-
mingen), or caspase activity (using a CaspACE FITC-VAD-FMK in
situ marker from Promega) according to the manufacturer’s instruc-
tions.
Redox-State Analysis and ROS Measurement
Reduced and oxidized glutathione levels and ROS levels were mea-
sured as detailed in the Supplemental Experimental Procedures.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and seven figures and can be found with
this article online at http://www.cell.com/cgi/content/full/126/1/107/
DC1/.
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